• 1.

    Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):1–12.

    CAS 

    Google Scholar
     

  • 2.

    WHO official updates—Coronavirus disease 2019. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

  • 3.

    Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 4.

    Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004;359(1447):1091–105.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 5.

    Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 6.

    Doroftei B, Ciobica A, Ilie O-D, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics. 2021;11(4):579.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39–44.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 8.

    Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.

    PubMed 

    Google Scholar
     

  • 9.

    Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:755.


    Google Scholar
     

  • 10.

    Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460–70.

    CAS 
    PubMed 

    Google Scholar
     

  • 11.

    Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–8.

    CAS 
    PubMed 

    Google Scholar
     

  • 12.

    Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–6.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325(12):1185–95.

    CAS 
    PubMed 

    Google Scholar
     

  • 14.

    Bansal V, Mahapure KS, Mehra I, Bhurwal A, Tekin A, Singh R, et al. Mortality benefit of convalescent plasma in COVID-19: a systematic review and meta-analysis. Front Med. 2021;8:250.


    Google Scholar
     

  • 15.

    Barreira DF, Lourenço RA, Calisto R, Moreira-Gonçalves D, Santos LL, Videira PA. Assessment of the safety and therapeutic benefits of convalescent plasma in COVID-19 treatment: a systematic review and meta-analysis. Front Med. 2021;8:660688.


    Google Scholar
     

  • 16.

    Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al., editors. The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clin Proc. Elsevier; 2021.

  • 17.

    Al-Riyami AZ, Schäfer R, van der Berg K, Bloch EM, Escourt LJ, Goel R, et al. Clinical use of convalescent plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sang. 2020;116:88–98.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 18.

    Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.


    Google Scholar
     

  • 19.

    Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):1–9.


    Google Scholar
     

  • 20.

    Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92:1475–83.

    CAS 
    PubMed 

    Google Scholar
     

  • 21.

    Chai KL, Valk SJ, Piechotta V, Kimber C, Monsef I, Doree C, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD013600.pub2.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 22.

    Jiang J, Miao Y, Zhao Y, Lu X, Zhou P, Zhou X, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications. Clin Transplant. 2020;34:e14025.

    CAS 
    PubMed 

    Google Scholar
     

  • 23.

    Kong Y, Cai C, Ling L, Zeng L, Wu M, Wu Y, et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transfus Apheresis Sci. 2020;59:102820.


    Google Scholar
     

  • 24.

    Clark E, Guilpain P, Filip L, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16981.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 25.

    Çınar OE, Sayınalp B, Aladağ Karakulak E, Avşar Karataş A, Velet M, İnkaya A, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfus Apheresis Sci. 2020;59:102821.


    Google Scholar
     

  • 26.

    Gharbharan A, Jordans CC, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FP, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12(1):1–12.


    Google Scholar
     

  • 27.

    Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, Spata E, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021.

  • 28.

    O’Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Investig. 2021. https://doi.org/10.1172/JCI150646.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood. 2020;136:755–9.

    CAS 
    PubMed 

    Google Scholar
     

  • 30.

    Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 31.

    Hung IF, To KK, Lee C-K, Lee K-L, Yan W-W, Chan K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest. 2013;144(2):464–73.

    PubMed 

    Google Scholar
     

  • 32.

    Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines. 2021;9(5):436.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    Pouladzadeh M, Safdarian M, Eshghi P, Abolghasemi H, Sheibani B, Choghakabodi PM, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med. 2021;16:2181–91.

    PubMed 

    Google Scholar
     

  • 34.

    Bandopadhyay P, D’Rozario R, Lahiri A, Sarif J, Ray Y, Paul SR, et al. Nature and dimensions of systemic hyperinflammation and its attenuation by convalescent plasma in severe COVID-19. J Infect Dis. 2021;224(4):565–74.

    CAS 
    PubMed 

    Google Scholar
     

  • 35.

    Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther. 2020;5(1):1–12.


    Google Scholar
     

  • 36.

    Jin H, Reed JC, Liu ST, Ho H-E, Lopes JP, Ramsey NB, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol In Pract. 2020;8(10):3594–6.


    Google Scholar
     

  • 37.

    Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis. 2020;96:131–5.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Mateos González M, Sierra Gonzalo E, Casado Lopez I, Arnalich Fernández F, Beato Pérez JL, Monge Monge D, et al. The prognostic value of eosinophil recovery in COVID-19: a multicentre, retrospective cohort study on patients hospitalised in Spanish hospitals. J Clin Med. 2021;10(2):305.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. Int J Lab Hematol. 2021;43:137–41.

    PubMed 

    Google Scholar
     

  • 41.

    Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH. Eosinopenia and COVID-19. J Am Osteopath Assoc. 2020;120(8):504–8.


    Google Scholar
     

  • 42.

    Mu T, Yi Z, Wang M, Wang J, Zhang C, Chen H, et al. Expression of eosinophil in peripheral blood of patients with COVID-19 and its clinical significance. J Clin Lab Anal. 2021;35(1):e23620.

    CAS 
    PubMed 

    Google Scholar
     

  • 43.

    Nair AP, Soliman A, Al Masalamani MA, De Sanctis V, Nashwan AJ, Sasi S, et al. Clinical outcome of eosinophilia in patients with COVID-19: a controlled study. Acta Bio Medica: Atenei Parmensis. 2020;91(4):e2020165.

    CAS 

    Google Scholar
     

  • 44.

    Dai W, Wu J, Li T, Shen J, Pang R, Luo T, et al. Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China. J Med Virol. 2021;93(4):2321–31.

    CAS 
    PubMed 

    Google Scholar
     

  • 45.

    Lindemann M, Krawczyk A, Dolff S, Konik M, Rohn H, Platte M, et al. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. J Med Virol. 2021;93(5):3047–54.

    CAS 
    PubMed 

    Google Scholar
     

  • 46.

    Mira E, Yarce OA, Ortega C, Fernández S, Pascual NM, Gómez C, et al. Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(8):2793.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 47.

    Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodríguez Y, Gallo JE, Salazar-Uribe JC, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 48.

    Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–6.

    CAS 
    PubMed 

    Google Scholar
     

  • 49.

    Joyner M, Wright RS, Fairweather D, Senefeld J, Bruno K, Klassen S, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. medRxiv. 2020.

  • 50.

    Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al., editors. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. Elsevier; 2020.

  • 51.

    Network WBR. Position paper on use of convalescent plasma, serum of immune globuline concentrates as an element in response to an emerging virus. 2017.

  • 52.

    Middelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang. 2011;100(3):327–35.

    CAS 
    PubMed 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)